This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Intralesional PV-10 Chemoablation of Metastatic Melanoma

This study has been completed.
Information provided by:
Provectus Pharmaceuticals Identifier:
First received: September 14, 2005
Last updated: August 22, 2007
Last verified: August 2007
The objective of this study is to investigate the safety of intralesional (IL) PV-10 for the treatment of metastatic melanoma. This study will also include a preliminary assessment of response of treated and untreated lesions by clinical evaluation at follow-up of 12 to 24 weeks following IL PV-10 treatment.

Condition Intervention Phase
Melanoma Drug: PV-10 (rose bengal disodium, 10%) Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Safety and Tolerability Study of Intralesional PV-10 Chemoablation in Subjects With Metastatic Melanoma

Resource links provided by NLM:

Further study details as provided by Provectus Pharmaceuticals:

Primary Outcome Measures:
  • Safety: adverse experience

Secondary Outcome Measures:
  • Efficacy: objective response rate of target lesions and untreated non-target lesions

Estimated Enrollment: 20
Study Start Date: August 2005
Study Completion Date: August 2007
Detailed Description:
This is a two center, open label, ascending dose study. Subjects with at least two measurable melanoma lesions will receive a single intralesional injection of 10% PV-10 solution into each of one to twenty (20) target lesions. Additionally, one to three measurable untreated non-target lesions will be followed for assessment of bystander response. Systemic and locoregional adverse events will be monitored over the study interval. Dose escalation will be made only if no subjects at the first dose level have a Grade 3 non-hematological or Grade 4 hematological toxicity over a period of two weeks after PV-10 administration. Subject accrual and PV-10 administration at the second dose level will be stopped if more than 1 subject has a treatment related Grade 3 non-hematological or Grade 4 hematological toxicity within a period of two weeks after PV-10 administration.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed metastatic melanoma, American Joint Committee on Cancer (AJCC) Stage III (regional lymph node metastasis, in-transit metastasis or satellite metastasis) or Stage IV (distant metastasis)
  • Measurable disease in at least two lesions, each lesion ≤ 6 cm in diameter
  • Performance status: ECOG 0-2
  • Life expectancy: at least 6 months
  • Hematopoietic:

    • White blood cell count (WBC) at least 3000/mm3
    • Absolute neutrophil count (ANC) at least 1.5 (1,500/mm3)
    • Platelet count at least 100,000/mm3
  • Renal function:

    • Creatinine ≤ 2.0 mg/dL
  • Hepatic function:

    • Bilirubin ≤ 2.0 mg/dL
    • AST/ALT ≤ 3 times the upper limit of normal (ULN)
  • Cardiovascular function:

    • No major cardiovascular disease
  • Thyroid function:

    • T3 (serum triiodothyronine), T4 (serum thyroxine) and THS (serum thyrotropin) within normal limits
  • Immunological function:

    • Adequate immune system function in the opinion of the investigator

Exclusion Criteria:

  • Radiation therapy within 4 weeks or to any study lesion within 12 weeks
  • Chemotherapy or other systemic cancer therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin) or regional chemotherapy (limb infusion or perfusion) within 12 weeks
  • Local treatment (e.g., surgery, cryotherapy, radiofrequency ablation) to the treatment area within 4 weeks
  • Investigational agents within 4 weeks (or 5 half-lives)
  • Anti-tumor vaccine therapy within 12 weeks
  • Concurrent illness:

    • Severe diabetes or extremity complications due to diabetes
    • Significant concurrent disease or illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the investigator, compromise subject safety or compliance or interfere with interpretation of study results
    • Thyroid autoregulatory dysfunction, including thyroid disease (subclinical or ongoing), goiter, partial thyroidectomy, prior radioiodine- or surgically-treated Graves' hyperthyroidism, or cystic fibrosis
    • Pregnancy or fertile female subjects who are not using effective contraception
  • Concurrent medications:

    • Subjects taking medications with a significant risk of photosensitization, such as thiazides, within one week (or 5 half-lives) of study treatment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00219843

Australia, New South Wales
Sydney Melanoma Unit
North Sydney, New South Wales, Australia, 2060
Newcastle Melanoma Unit
Waratah, New South Wales, Australia, 2298
Sponsors and Collaborators
Provectus Pharmaceuticals
Study Director: Eric Wachter, Ph.D. Provectus Pharmaceuticals
  More Information Identifier: NCT00219843     History of Changes
Other Study ID Numbers: PV-10-MM-01
Study First Received: September 14, 2005
Last Updated: August 22, 2007

Keywords provided by Provectus Pharmaceuticals:
Stage III and IV melanoma

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas processed this record on August 17, 2017